
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Axel Hauschild

Lung cancer immunotherapy test standardization: the Blueprint PD-L1 IHC Assay Comparison Project
Fred Hirsch

Evaluating the experience of surviving at least five years after a prostate cancer diagnosis
Natalie Doyle

Balancing the benefits and costs of immunotherapy in the treatment of lung cancer
Rolf Stahel

SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations
Paolo Ascierto